The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE）

This is a multicenter, double-blind, randomized, placebo-controlled phase Ⅱ study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of YN-011 in subjects with overweight (27 kg/m2 ≤ BMI \< 30 kg/m2, with at least one comorbidity) or obesity (BMI ≥ 30 kg/m2, with or without comorbidities). The entire study period will consist of a 2-week screening period, a 22-week double-blind treatment period, and a 4-week off-treatment follow-up period

NCT Number	NCT07114419
Lead Sponsor	Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions	Obesity and Overweight
Enrollment	200 participants
Start Date	2025-08-25
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-02